Where it acts / mechanism
What semaglutide does (mechanism of action)
Why it matters clinically
Canadian authority citing this mechanism*
GLP‑1 receptor (overall)
Semaglutide is a GLP‑1 receptor agonist (GLP‑1 analogue) that binds to and activates the GLP‑1 receptor, mimicking the action of natural GLP‑1 released after a meal.
Activating the GLP‑1 receptor drives a coordinated response that lowers blood glucose and supports weight loss, making it useful in type 2 diabetes management.
Health Canada product monographs (e.g., Ozempic, Wegovy) describe semaglutide as a “glucagon‑like peptide‑1 (GLP‑1) receptor agonist” used for type 2 diabetes and weight management
Pancreatic beta cells (insulin)
When blood glucose is elevated, semaglutide enhances glucose‑dependent insulin secretion from pancreatic beta cells via GLP‑1 receptor activation.
More insulin is released only when glucose is high, which lowers blood sugar with a lower risk of hypoglycaemia compared with drugs that stimulate insulin regardless of glucose level.
Canadian clinical guidance for GLP‑1 receptor agonists (including semaglutide) notes they “increase glucose‑dependent insulin secretion” in type 2 diabetes
Pancreatic alpha cells (glucagon)
Semaglutide suppresses inappropriate glucagon secretion from pancreatic alpha cells when glucose is high.
Lower glucagon reduces hepatic (liver) glucose output, contributing to improved fasting and post‑meal blood glucose control.
Canadian endocrinology and diabetes overviews of GLP‑1 RAs state they “reduce inappropriately elevated glucagon” as a key mechanism for lowering blood glucose in type 2 diabetes
Stomach / gut (gastric emptying)
Semaglutide slows gastric emptying through GLP‑1 receptor action in the gastrointestinal tract.
Food moves more slowly from the stomach to the intestine, which blunts post‑meal (post‑prandial) glucose spikes and improves satiety.
Health Canada labelling for GLP‑1 RAs used in Canada (including semaglutide) notes delayed gastric emptying as a mechanism affecting post‑prandial glycaemia
Brain (appetite and satiety)
In the brain, semaglutide activates GLP‑1 receptors in appetite‑regulation centres, increasing satiety and reducing appetite.
Patients tend to eat less and feel full sooner, which reduces caloric intake and supports clinically meaningful weight loss, particularly relevant where obesity and type 2 diabetes coexist.
Canadian obesity and diabetes guidance describing GLP‑1 RAs (including semaglutide) highlight central appetite effects leading to “reduced energy intake and weight loss”
Overall glucose control
By combining increased insulin (when glucose is high), reduced glucagon, slower gastric emptying and reduced intake, semaglutide lowers fasting and post‑meal blood glucose and improves HbA1c.
Better glycaemic control reduces risk of diabetes complications (e.g., cardiovascular, kidney and eye disease), which can lower long‑term health and disability costs for employers.
Health Canada‑authorised Product Monographs for semaglutide list improved HbA1c and fasting/post‑prandial glucose as primary efficacy outcomes in type 2 diabetes
Body weight / cardiometabolic risk
Through reduced appetite and energy intake, semaglutide leads to clinically significant weight loss, particularly at obesity‑indicated doses.
Weight reduction can improve blood pressure, lipids and glycaemic control, potentially lowering cardiometabolic risk and related claims over time.
Health Canada approvals of higher‑dose semaglutide for weight management, together with Canadian obesity guidelines, describe sustained weight loss via GLP‑1–mediated appetite reduction and energy‑intake lowering